BBC - Virtus Biotech Clinical Trials ETF
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies. Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
As of May 15, 2026: spot at $42.36, ATM IV 39.3%, max pain $36.00, net GEX $4.8K.
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $38.2M
- Beta
- 1.22
- 52-Week Range
- 16.85-48.18
- Dividend Yield
- $0.66
- IPO Date
- Dec 17, 2014
- Exchange
- AMEX
What BBC Looks Like to Options Traders Today
IV rank of 31.2% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($4.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.000) is roughly flat across the wings.
What This Page Covers
The BBC overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.
Frequently asked BBC overview questions
- What is BBC?
- BBC is the ticker symbol for Virtus Biotech Clinical Trials ETF, an listed exchange-traded fund. The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies. Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF. Listed on AMEX. BBC is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
- What does the BBC options snapshot look like today?
- As of May 15, 2026, the BBC options snapshot shows spot at $42.36, ATM IV 39.3%, IV rank 31.2%, max pain $36.00, net GEX $4.8K, expected move 11.27%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are BBC's key statistics?
- Virtus Biotech Clinical Trials ETF (BBC) carries a market capitalization of $38.2M, 52-week range of 16.85-48.18. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
- What sector or industry does BBC belong to?
- Virtus Biotech Clinical Trials ETF operates in the Financial Services sector, in the Asset Management industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare BBC's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the BBC data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.